The FDA on Jan. 27 approved Eli Lilly’s BTK inhibitor Jaypirca for the treatment of mantle cell lymphoma in patients that have already received at least two previous therapies, including one of the three other BTK inhibitors on the market. While BeiGene’s Brukinsa, AstraZeneca’s Calquence and AbbVie and J&J’s joint venture Imbruvica already make up a strong blood cancer market basket, Lilly is targeting a different group of patients, as Jaypirca is the first non-covalent BTK inhibitor, meaning it can be used sequentially in patients whose disease failed to be treated by one of the other three therapies. For the treatment of mantle cell lymphoma, Imbruvica is the most advantaged BTK inhibitor, holding covered or better status for virtually all (99%) insured lives under the pharmacy benefit. 17% of lives have preferred access to Imbruvica, growing to 45% with utilization management restrictions applied.
SOURCE: MMIT Analytics, as of 1/30/23